Literature DB >> 618710

Effect of pleural effusion on high-dose methotrexate kinetics.

W E Evans, C B Pratt.   

Abstract

The kinetics of methotrexate were followed in a patient given two 6-hr infusions of 400 mg/kg in the presence and absence of a pleural effusion. Although the decline in serum concentrations during the first 30 hr after the infusion was similar for the two treatment courses, the half-life beginning 30 hr after the infusion was 6.7 hr without the pleural effusion and 14.4 hr with the pleural effusion. Comparison of the intercompartment distribution rate constants indicated slower movement of the drug back into the central compartment from the peripheral compartment when a pleural effusion was present. Pleural fluid methotrexate concentrations were consistently higher than serum concentrations. These data indicate that the increased risk of toxicity following high-dose methotrexate in patients with pleural effusions is due to changes in methotrexate kinetics resulting in delayed excretion.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 618710     DOI: 10.1002/cpt197823168

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

Review 1.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 2.  Determining the optimal dose in the development of anticancer agents.

Authors:  Ron H J Mathijssen; Alex Sparreboom; Jaap Verweij
Journal:  Nat Rev Clin Oncol       Date:  2014-03-25       Impact factor: 66.675

3.  Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.

Authors:  Karen D Wright; John C Panetta; Arzu Onar-Thomas; Wilburn E Reddick; Zoltan Patay; Ibrahim Qaddoumi; Alberto Broniscer; Giles Robinson; Frederick A Boop; Paul Klimo; Deborah Ward; Amar Gajjar; Clinton F Stewart
Journal:  Cancer Chemother Pharmacol       Date:  2014-10-24       Impact factor: 3.333

4.  Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.

Authors:  W E Evans; C B Pratt; R H Taylor; L F Barker; W R Crom
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 5.  Pharmacokinetics of haemoperfusion for drug overdose.

Authors:  S Pond; J Rosenberg; N L Benowitz; S Takki
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

Review 6.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

7.  Determination of Methotrexate, 7-Hydroxymethotrexate, and 2,4-Diamino-N10-methylpteroic Acid by LC-MS/MS in Plasma and Cerebrospinal Fluid and Application in a Pharmacokinetic Analysis of High-Dose Methotrexate.

Authors:  Michael S Roberts; Nicholas S Selvo; Jessica K Roberts; Vinay M Daryani; Thandranese S Owens; K Elaine Harstead; Amar Gajjar; Clinton F Stewart
Journal:  J Liq Chromatogr Relat Technol       Date:  2016-10-10       Impact factor: 1.312

Review 8.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

Review 9.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

10.  Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia.

Authors:  Samantha N Reiss; Larry W Buie; Nelly Adel; Debra A Goldman; Sean M Devlin; Dan Douer
Journal:  Ann Hematol       Date:  2016-08-20       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.